Chart predicting double prices, page-25

Nows the time to buy more and move your average down . At the current SP AHZ is a steal if I had more cash in hand I would be buying more . Once AHZ does their first in human TAVR there will be without a doubt a massive increase in the SP People have criticised WP for what’s happened here but really he inherited a train wreck when he got the job . The immuno has turned out to be impossible to sell or find a partner and the infusion pump distributorship side of the company was never going to be a big money maker . WP has now done what needed to be done and kept his focus on retaining the things with real value , the ADAPT IP and the TAVR . Ultimately I can see this company being worth many dollars a share IMO